Johnson & Johnson to present neuropsychiatry data at Psych Congress 2026
- Johnson & Johnson will present 24 abstracts at the Psych Congress Annual Meeting (Sept 15–19, 2026) in New Orleans.
- Pivotal Phase 3 data for CAPLYTA (lumateperone) in acute bipolar I mania will be presented, alongside additional CAPLYTA analyses across bipolar depression and MDD.
- Analyses of SPRAVATO (esketamine) on anhedonia and Phase 3 clinical trial data for seltorexant in MDD with insomnia symptoms will be shown.
- A supplemental NDA for CAPLYTA with long‑term data showing reduced risk of relapse in schizophrenia has been approved by the FDA.
Conference participation
Johnson & Johnson will present 24 abstracts featuring clinical data and real‑world evidence across its neuropsychiatry portfolio at the Psych Congress Annual Meeting (September 15–19, 2026) in New Orleans.
Key clinical findings
New pivotal Phase 3 data evaluating CAPLYTA (lumateperone) in the acute treatment of manic episodes or manic episodes with mixed features associated with bipolar I disorder will be presented. Additional CAPLYTA data will cover adjunctive use in MDD across depressive symptoms, remission, patient subgroups and metabolic outcomes.
New analyses of SPRAVATO (esketamine) nasal spray will examine its impact on anhedonia, and Phase 3 clinical trial data for seltorexant will be presented for major depressive disorder with insomnia symptoms.
Real‑world evidence and long‑acting injectables
Presented real‑world studies will include CAPLYTA treatment patterns in bipolar depression (dosing and duration) and LAI studies assessing schizophrenia‑related hospitalizations in young dual‑eligible patients before LAI initiation, subsequent relapse risk, and treatment satisfaction with LAIs. The company will support educational programs, in‑booth presentations and training, including interactive PRIDE LAI visualizations and CAPLYTA schizophrenia and network meta‑analysis findings.
Regulatory and usage notes
A supplemental NDA for CAPLYTA containing long‑term data on delayed time to relapse in schizophrenia was recently approved by the U.S. FDA. SPRAVATO has been approved in more than 70 markets and administered to over 250,000 patients worldwide. The full list of presentations is available on JNJ.com.
Source: J&J
